Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 90

1.

Phase 2 open-label study of weekly docosahexaenoic acid-paclitaxel in patients with metastatic uveal melanoma.

Homsi J, Bedikian AY, Papadopoulos NE, Kim KB, Hwu WJ, Mahoney SL, Hwu P.

Melanoma Res. 2010 Dec;20(6):507-10. doi: 10.1097/CMR.0b013e3283403ce9.

PMID:
20881508
2.

Phase 2 open-label study of weekly docosahexaenoic acid-paclitaxel in cutaneous and mucosal metastatic melanoma patients.

Homsi J, Bedikian AY, Kim KB, Papadopoulos NE, Hwu WJ, Mahoney SL, Hwu P.

Melanoma Res. 2009 Aug;19(4):238-42. doi: 10.1097/CMR.0b013e32832a1e2f.

PMID:
19521262
3.

Phase II trial of weekly paclitaxel in patients with advanced melanoma.

Walker L, Schalch H, King DM, Dietrich L, Eastman M, Kwak M, Kim K, Albertini MR.

Melanoma Res. 2005 Oct;15(5):453-9.

PMID:
16179874
4.

A phase 2 clinical trial of nab-paclitaxel in previously treated and chemotherapy-naive patients with metastatic melanoma.

Hersh EM, O'Day SJ, Ribas A, Samlowski WE, Gordon MS, Shechter DE, Clawson AA, Gonzalez R.

Cancer. 2010 Jan 1;116(1):155-63. doi: 10.1002/cncr.24720.

5.
6.

Phase II study of weekly paclitaxel plus 24-h continuous infusion 5-fluorouracil, folinic acid and 3-weekly cisplatin for the treatment of patients with advanced gastric cancer.

Honecker F, Kollmannsberger C, Quietzsch D, Haag C, Schroeder M, Spott C, Hartmann JT, Baronius W, Hempel V, Kanz L, Bokemeyer C.

Anticancer Drugs. 2002 Jun;13(5):497-503.

PMID:
12045461
7.

A phase II open-label study of DHA-paclitaxel (Taxoprexin) by 2-h intravenous infusion in previously untreated patients with locally advanced or metastatic gastric or oesophageal adenocarcinoma.

Jones RJ, Hawkins RE, Eatock MM, Ferry DR, Eskens FA, Wilke H, Evans TR.

Cancer Chemother Pharmacol. 2008 Mar;61(3):435-41. Epub 2007 Apr 18.

PMID:
17440725
8.

Phase II, randomized, controlled, double-blinded trial of weekly elesclomol plus paclitaxel versus paclitaxel alone for stage IV metastatic melanoma.

O'Day S, Gonzalez R, Lawson D, Weber R, Hutchins L, Anderson C, Haddad J, Kong S, Williams A, Jacobson E.

J Clin Oncol. 2009 Nov 10;27(32):5452-8. doi: 10.1200/JCO.2008.17.1579. Epub 2009 Oct 13.

PMID:
19826135
9.

Salvage weekly paclitaxel in recurrent ovarian cancer.

Abu-Rustum NR, Aghajanian C, Barakat RR, Fennelly D, Shapiro F, Spriggs D.

Semin Oncol. 1997 Oct;24(5 Suppl 15):S15-62-S15-67.

PMID:
9346225
10.

Paclitaxel in metastatic breast cancer: a trial of two doses by a 3-hour infusion in patients with disease recurrence after prior therapy with anthracyclines.

Gianni L, Munzone E, Capri G, Villani F, Spreafico C, Tarenzi E, Fulfaro F, Caraceni A, Martini C, Laffranchi A, et al.

J Natl Cancer Inst. 1995 Aug 2;87(15):1169-75.

PMID:
7674322
11.
12.

A phase II study of bortezomib in the treatment of metastatic malignant melanoma.

Markovic SN, Geyer SM, Dawkins F, Sharfman W, Albertini M, Maples W, Fracasso PM, Fitch T, Lorusso P, Adjei AA, Erlichman C.

Cancer. 2005 Jun 15;103(12):2584-9.

13.

Phase 1 and pharmacokinetic study of weekly docosahexaenoic acid-paclitaxel, Taxoprexin, in resistant solid tumor malignancies.

Fracasso PM, Picus J, Wildi JD, Goodner SA, Creekmore AN, Gao F, Govindan R, Ellis MJ, Tan BR, Linette GP, Fu CJ, Pentikis HS, Zumbrun SC, Egorin MJ, Bellet RE.

Cancer Chemother Pharmacol. 2009 Feb;63(3):451-8. doi: 10.1007/s00280-008-0756-0. Epub 2008 Apr 15.

PMID:
18414864
14.

Paclitaxel and cisplatin in patients with recurrent and metastatic head and neck squamous cell carcinoma.

Adamo V, Ferraro G, Pergolizzi S, Sergi C, Laudani A, Settineri N, Alafaci E, Scimone A, Spano F, Spitaleri G.

Oral Oncol. 2004 May;40(5):525-31.

PMID:
15006626
15.

Phase I/II study with paclitaxel in combination with weekly high-dose 5-fluorouracil/folinic acid in the treatment of metastatic breast cancer: an interim analysis.

Klaassen U, Wilke H, Pari CP, Strumberg D, Harstrick A, Eberhardt W, Becher R, Diergarten K, Seeber S.

Semin Oncol. 1995 Dec;22(6 Suppl 14):7-11.

PMID:
8553083
16.

Vinorelbine and cisplatin (CIVIC regimen) for the treatment of metastatic breast carcinoma after failure of anthracycline- and/or paclitaxel-containing regimens.

Ray-Coquard I, Biron P, Bachelot T, Guastalla JP, Catimel G, Merrouche Y, Droz JP, Chauvin F, Blay JY.

Cancer. 1998 Jan 1;82(1):134-40.

PMID:
9428489
17.

Phase II study of biweekly plitidepsin as second-line therapy in patients with advanced malignant melanoma.

Eisen T, Thomas J, Miller WH Jr, Gore M, Wolter P, Kavan P, MartĂ­n JA, Lardelli P.

Melanoma Res. 2009 Jun;19(3):185-92. doi: 10.1097/CMR.0b013e32832bbde6.

PMID:
19436178
18.

An active regimen of weekly paclitaxel and estramustine in metastatic androgen-independent prostate cancer.

Vaishampayan U, Fontana J, Du W, Hussain M.

Urology. 2002 Dec;60(6):1050-4.

PMID:
12475668
19.

Weekly epirubicin and paclitaxel with granulocyte colony-stimulating factor support in previously untreated metastatic breast cancer patients: a phase II study.

Nisticò C, Bria E, Cuppone F, Fornier M, Sperduti I, Carpino A, Pace A, Cognetti F, Terzoli E.

Anticancer Drugs. 2007 Jul;18(6):687-92.

PMID:
17762397
20.

A phase II evaluation of weekly paclitaxel plus carboplatin in advanced urothelial cancer.

Friedland DM, Dakhil S, Hollen C, Gregurich MA, Asmar L.

Cancer Invest. 2004;22(3):374-82.

PMID:
15493358

Supplemental Content

Support Center